Phio Pharmaceuticals (PHIO)

• Market cap: $3.08M
• 1 day: 7.35%
• 5 days: 13.62%
• 1 month: -9.03%
• 3 months: 10.61%
• 6 months: -58.35%
• Year to date: -57.86%
• 1 year: -71.03%
• 5 years: -99.65%
• 10 years: -100.00%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.

Employees: 9

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.35% less ownership

Funds ownership: 3.66% [Q2] → 3.31% (-0.35%) [Q3]

16% less capital invested

Capital invested by funds: $117K [Q2] → $98.3K (-$18.6K) [Q3]

50% less funds holding

Funds holding: 12 [Q2] → 6 (-6) [Q3]

75% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 8

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4